Open Access杜拉鲁肽每周一次治疗基线体重指数较低的成年2型糖尿病患者的疗效和安全性
Author(s) -
Shi Yongquan,
Liu Siying,
Zhu Jiankun,
Hong Tianpei
Publication year - 2021
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.13147
Subject(s) - medicine , dulaglutide , body mass index , glycated hemoglobin , type 2 diabetes , diabetes mellitus , obesity , incidence (geometry) , hypoglycemia , exenatide , endocrinology , physics , optics
Highlights In Chinese patients with type 2 diabetes (T2D) and body mass index (BMI) <25 kg/m 2 , dulaglutide demonstrated great improvements in glycemic control with mild body weight reduction and low hypoglycemia risk. The results indicate that dulaglutide is effective and safe in patients with T2D and lower BMI; therefore, BMI should not be a consideration when dulaglutide is prescribed to Chinese patients with T2D.